


AMENDMENTS TO THE CLAIMS

1. (Currently amended) Compounds A compound of General Formula 1:

**General Formula 1**

wherein:

Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C₁₋₇-alkyl, aryl-C₁₋₇-alkyl, or (*E*)-2-aryl-ethen-1-yl, and the substituent in position 6 is hydrogen or C₁₋₇-alkyl;

X represents aryl; aryl-C₁₋₇-alkyl-; aryl-O-; aryl-C₁₋₇-alkyl-O-; R¹-SO₂NR²-; R¹-CONR²-; aryl-R⁸-CONR²-; R¹-NR³CONR²-; R¹-NR²CO-; or X and Z represent together with the carbon atom to which they are attached an exocyclic double bond which bears an aryl substituent at the thus formed methylene group;

Z represents hydrogen; in case X represents aryl or aryl-C₁₋₇-alkyl Z represents hydrogen, hydroxyl, carboxyl or R⁴-NR⁵CO-; in case X represents R¹-NR²CO- Z represents hydrogen or C₁₋₇-alkyl; or in case X represents aryl or aryl-C₁₋₇-alkyl and n represents the number 0, Z represents hydrogen, hydroxyl, carboxyl, R⁴-NR⁵CO-, aryl or aryl-C₁₋₇-alkyl;

Y represents -C(R⁶)(R⁷)(CH₂)_m- or -(CH₂)_mC(R⁶)(R⁷)-;

m represents the numbers 1 or 2;

n represents the numbers 0 or 1;

R¹ represents aryl or aryl-C₁₋₇-alkyl;

R² represents hydrogen; C₁₋₇-alkyl; 2-hydroxyethyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;

R^3 represents hydrogen or C_{1-7} -alkyl;

R^4 represents hydrogen; C_{1-7} -alkyl; aryl; aryl- C_{1-7} -alkyl; or forms together with R^5 a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R^4 and R^5 are attached as ring atom;

R^5 represents hydrogen; C_{1-7} -alkyl; 2-hydroxyethyl; or forms together with R^4 a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R^4 and R^5 are attached as ring atom;


R^6 represents hydrogen; C_{1-7} -alkyl; aryl; aryl- C_{1-7} -alkyl; or forms together with R^7 a saturated carbocyclic ring including the carbon atom to which R^6 and R^7 are attached as ring atom;

R^7 represents hydrogen; methyl; or forms together with R^6 a saturated carbocyclic ring including the carbon atom to which R^6 and R^7 are attached as ring atom[.]; and

R^8 represents a saturated carbocyclic ring[.];

[[and]] or optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, [[and]] or mixtures of diastereomeric racemates, of said compound; as well as their or pharmaceutically acceptable salts, solvent complexes, [[and]] or morphological forms, of said compound.

2. (Currently amended) ~~Compounds~~ A compound of General Formula 2 according to claim 1:



General Formula 2

wherein:

Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C₁₋₇-alkyl or aryl-C₁₋₇-alkyl and the substituent in position 6 is methyl or ethyl;

X represents aryl; aryl-C₁₋₇-alkyl-; aryl-O-; aryl-C₁₋₇-alkyl-O-; R¹-SO₂NR²-; R¹-CONR²-; aryl-R⁸-CONR²-; R¹-NR³CONR²-; or R¹-NR²CO-;

Z represents hydrogen; in case X represents aryl or aryl-C₁₋₇-alkyl and n represents the number 1 Z represents hydrogen, hydroxyl or R⁴-NR⁵CO-;

n represents the numbers 0 or 1;

R¹ represents aryl or aryl-C₁₋₇-alkyl;

R² represents hydrogen; C₁₋₇-alkyl; 2-hydroxyethyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;


R³ represents hydrogen or C₁₋₇-alkyl;

R⁴ represents hydrogen; C₁₋₇-alkyl; aryl; aryl-C₁₋₇-alkyl; or forms together with R⁵ a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R⁴ and R⁵ are attached as ring atom;

R⁵ represents hydrogen; C₁₋₇-alkyl; 2-hydroxyethyl; or forms together with R⁴ a saturated 4-, 5- or 6-membered ring including the nitrogen atom to which R⁴ and R⁵ are attached as ring atom[.]; and

R⁸ represents a saturated carbocyclic ring.


3. (Currently amended) ~~Compounds~~ A compound of General Formula 3 according to claim 1:



General Formula 3

wherein n, Y, Z and Py have the meaning given in General Formula 1.


4. (Currently amended) ~~Compounds~~ A compound of General Formula 4 according to claim 1:



General Formula 4

wherein n, Y, Z and Py have the meaning given in General Formula 1.


5. (Currently amended) ~~Compounds~~ A compound of General Formula 5 according to claim 1:



General Formula 5

wherein R², Y, n and Py have the meaning given in General Formula 1.

6. (Currently amended) ~~Compounds~~ A compound of General Formula 6 according to claim 1:




General Formula 6

wherein R⁴, R⁵, Y, n and Py have the meaning given in General Formula

1.

7. (Currently amended) ~~Compounds~~ A compound of General Formula 7 according to claim 1:




General Formula 7

wherein R¹, R², Z, Y, n and Z have the meaning given in General Formula

1.

8. (Currently amended) ~~Compounds~~ A compound of General Formula 8 according to claim 1:




General Formula 8

wherein R¹, R², n, Y and Py have the meaning given in General Formula

1.


9. (Currently amended) ~~Compounds~~ A compound of General Formula 9 according to claim 1:



General Formula 9

wherein X, Y, Z, n and Py have the meaning given in General Formula 1.


10. (Currently amended) ~~Compounds~~ A compound of General Formula 10 according to claim 1:



General Formula 10

wherein X, Y, Z, n and Py have the meaning given in General Formula 1.


11. (Currently amended) ~~Compounds~~ A compound of General Formula 11 according to claim 1:



General Formula 11

wherein X, Y, Z, n and Py have the meaning given in General Formula 1.


12. (Currently amended) ~~Compounds~~ A compound of General Formula 12 according to claim 1:



General Formula 12

wherein n, Z and Py have the meaning given in General Formula 2.


13. (Currently amended) ~~Compounds~~ A compound of General Formula 13 according to claim 1:



General Formula 13

wherein n, Z and Py have the meaning given in General Formula 2.


14. (Currently amended) ~~Compounds~~ A compound of General Formula 14 according to claim 1:



General Formula 14

wherein R², n and Py have the meaning given in General Formula 2.


15. (Currently amended) ~~Compounds~~ A compound of General Formula 15 according to claim 1:



General Formula 15


wherein R⁴, R⁵, n and Py have the meaning given in General Formula 2.

16. (Currently amended) ~~Compounds~~ A compound of General Formula 16 according to claim 1:

**General Formula 16**


wherein R^1 , R^2 , Z, n and Z have the meaning given in General Formula 2.

17. (Currently amended) ~~Compounds~~ A compound of General Formula 17 according to claim 1:

**General Formula 17**


wherein R^1 , R^2 , n and Py have the meaning given in General Formula 2.

18 (Currently amended) ~~Compounds~~ A compound of General Formula 18 according to claim 1:

**General Formula 18**


wherein X, Z and Py have the meaning given in General Formula 2.

19. (Currently amended) ~~Compounds~~ A compound of General Formula 19 according to claim 1:

**General Formula 19**


wherein X, Z and n have the meaning given in General Formula 2.

20. (Currently amended) ~~Compounds~~ A compound of General Formula 20 according to claim 1:

**General Formula 20**


wherein X, Z and n have the meaning given in General Formula 2.

21. (Currently amended) ~~Compounds~~ A compound of General Formula 21 according to claim 1:

**General Formula 21**


wherein R¹ and R² have the meaning given in General Formula 2.

22. (Currently amended) ~~Compounds~~ A compound of General Formula 22 according to claim 1:

**General Formula 22**


wherein R^2 and n have the meaning given in General Formula 2.

23. (Currently amended) ~~Compounds~~ A compound of General Formula 23 according to claim 1:

**General Formula 23**


wherein Z has the meaning given in General Formula 2.

24. (Currently amended) ~~Compounds~~ A compound of General Formula 24 according to claim 1:

**General Formula 24**

wherein Z has the meaning given in General Formula 2.

25. (Currently amended) ~~Compounds of the~~ A compound of General Formula 25[[]]:



General Formula 25

wherein:

Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C₁₋₇-alkyl, aryl-C₁₋₇-alkyl, or (*E*)-2-aryl-ethen-1-yl, and the substituent in position 6 is hydrogen or C₁₋₇-alkyl;

X represents aryl; aryl-O-; aryl-C₁₋₇-alkyl-; R¹-SO₂NR²-; R¹-CONR²-; R¹-NR³CONR²-; R¹-NR²CO-; or X and Z represent together with the carbon atom to which they are attached an exocyclic double bond which bears an aryl substituent at the thus formed methylene group;

Y represents -C(R⁴)(R⁵)(CH₂)_m- or -(CH₂)_mC(R⁴)(R⁵)-;

Z represents hydrogen; in case X represents aryl or aryl-C₁₋₇-alkyl Z represents hydrogen, hydroxyl, carboxyl, R¹-NR²CO-; or in case X represents aryl or aryl-C₁₋₇-alkyl and n represents the number 0, Z represents hydrogen, hydroxyl, carboxyl, R¹-NR²CO-, aryl, aryl-C₁₋₇-alkyl;

n represents the numbers 0 or 1;

m represents the numbers 1 or 2;

R¹ represents aryl; C₁₋₇-alkyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;

R² and R³ represent independently hydrogen; C₁₋₇-alkyl; aryl-C₁₋₇-alkyl; or a saturated carbocyclic ring;

R⁴ represents hydrogen; C₁₋₇-alkyl; aryl; aryl-C₁₋₇-alkyl; or forms together with R⁵ a saturated carbocyclic ring including the carbon atom to which R⁴ and R⁵ are attached as ring atom; and

R⁵ represents hydrogen; methyl; or forms together with R⁴ a saturated carbocyclic ring including the carbon atom to which R⁴ and R⁵ are attached as ring atom[[:]],

[[and]] or configurational isomers, optically pure enantiomers or diastereomers, mixtures of enantiomers or diastereomers, diastereomeric racemates, [[and]] or mixtures of diastereomeric racemates, of said compound; as well as their or pharmaceutically acceptable salts, solvent complexes, [[and]] or morphological forms, of said compound.

26. (Currently amended) [[The]] A compound according to any one of claims 1 to 25 that is selected from the group consisting of:

- 1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2,6-dimethyl-pyridin-4-yl)-urea;
- 1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-*N*-propyl-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-*N*-propyl-benzenesulfonamide;
- 1-(2,6-Dimethyl-pyridin-4-yl)-3-[2-(3,3-diphenyl-pyrrolidin-1-yl)-ethyl]-urea;
- 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2,6-dimethyl-pyridin-4-yl)-urea;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-benzenesulfonamide;
- N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-fluoro-benzenesulfonamide;
- 1-(2-{3-[2-Methyl-6-((*E*)-styryl)-pyridin-4-yl]-ureido}-ethyl)-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;
- N*-Ethyl-4-methoxy-*N*-(1-{2-[3-(2-methyl-6-phenethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;
- 1-{2-[3-(2-Methyl-6-propyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;
- 1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-methyl-6-propyl-pyridin-4-yl)-urea;
- N*-Ethyl-4-methoxy-*N*-(1-{2-[3-(2-methyl-6-propyl-pyridin-4-yl)-ureido]-ethyl}-

piperidin-4-yl)-benzenesulfonamide;
1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-ethyl-6-methyl-pyridin-4-yl)-urea;
N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-benzenesulfonamide;
1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;
1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-phenethyl-pyridin-4-yl)-urea;
1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-{2-[2-(4-fluoro-phenyl)-ethyl]-pyridin-4-yl}-urea;
1-{2-[3-(2-Methyl-6-phenethyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;
2-(4-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-benzenesulfonamide;
1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-(2-hydroxy-ethyl)-amide;
1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-(2-hydroxy-ethyl)-amide;
N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-benzenesulfonamide;
1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2,6-diethyl-pyridin-4-yl)-urea;
N-(1-{2-[3-(2,6-Diethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-benzenesulfonamide;
N-(1-{2-[3-(2,6-Diethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-fluoro-benzenesulfonamide;
N-(1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-*N*-propyl-benzenesulfonamide;
4-Bromo-*N*-ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;
N-(1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-*N*-propyl-benzenesulfonamide;
N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-*N*-methyl-benzenesulfonamide;
N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-ethyl-*N*-

methyl-benzenesulfonamide_i

N-(4-[(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-sulfamoyl]-phenyl)-acetamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-isopropoxy-*N*-methyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-*N*-dimethyl-benzenesulfonamide_i

4-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-benzenesulfonamide_i

3,4-Dichloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-4-trifluoromethyl-benzenesulfonamide_i

5-Chloro-thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide_i

2,5-Dichloro-thiophene-3-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-fluoro-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-fluoro-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2,4-difluoro-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-difluoro-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2,6-difluoro-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-*N*-diethyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-isopropoxy-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-

methyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-2,3,6-trimethyl-benzenesulfonamide_i

4-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide_i

3-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide_i

2-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide_i

3,4-Dichloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-trifluoromethyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-trifluoromethyl-benzenesulfonamide

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-trifluoromethyl-benzenesulfonamide_i

Thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide_i

5-Chloro-thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide_i

2,5-Dichloro-thiophene-3-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2,5-dimethoxy-benzenesulfonamide_i

5-Bromo-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methoxy-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methoxy-4-methyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-dimethoxy-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-methoxy-benzenesulfonamide_i

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-

4-yl)-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-fluoro-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,4-difluoro-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,6-difluoro-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-ethyl-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-isopropoxy-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methyl-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methyl-benzenesulfonamide;
4-Chloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;
3-Chloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;
2-Chloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;
3,4-Dichloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-trifluoromethyl-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-trifluoromethyl-benzenesulfonamide;
5-Chloro-thiophene-2-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;
2,5-Dichloro-thiophene-3-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-

4-yl)-2,5-dimethoxy-benzenesulfonamide;
N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4-methyl-benzenesulfonamide;
N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4-methyl-benzenesulfonamide;
N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-dimethoxy-benzenesulfonamide;
N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-benzenesulfonamide;
1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;
2-(4-Chloro-phenyl)-*N*-ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-isobutyramide;
2-(3,4-Dichloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide;
2-(4-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-isobutyramide;
1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;
1-Phenyl-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;
1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;
2-(4-Chloro-phenyl)-*N*-ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide;
2-(4-Chloro-phenyl)-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-isobutyramide;
2-(4-Chloro-phenyl)-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide;
1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;
1-Phenyl-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide; and
N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methoxy-benzenesulfonamide;

27. (Currently amended) ~~[[The]]~~ A compound according to any one of claims 4 to 25 that is selected from the group consisting of:

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-(4-methoxy-phenyl)-acetamide;

4-Ethyl-1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidine-4-carboxylic acid benzyl-(2-hydroxy-ethyl)-amide;

1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-ethyl-6-methyl-pyridin-4-yl)-urea;

1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2,6-diethyl-pyridin-4-yl)-urea;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-*N*-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-dimethoxy-*N*-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4,*N*-dimethyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-*N*-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-fluoro-*N*-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-fluoro-*N*-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,4-difluoro-*N*-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-difluoro-*N*-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,6-difluoro-*N*-methyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,*N*-dimethyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,*N*-dimethyl-benzenesulfonamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-2,3,6,*N*-tetramethyl-benzenesulfonamide;

3-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-benzenesulfonamide_i

2-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-benzenesulfonamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-3-trifluoromethyl-benzenesulfonamide_i

Thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide_i

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-fluoro-benzenesulfonamide_i

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-difluoro-benzenesulfonamide

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methyl-benzenesulfonamide_i

N-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-trifluoromethyl-benzenesulfonamide_i

Thiophene-2-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide_i

2-(3,4-Dichloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-acetamide_i

1-Phenyl-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide_i

1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide_i

2-(4-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-acetamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-(4-fluoro-phenyl)-*N*-methyl-acetamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-2-phenyl-acetamide_i

2-(3-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-acetamide_i

2-(2-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide_i

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(2-methoxy-phenyl)-acetamide_i

1-Phenyl-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-phenyl-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(4-methoxy-phenyl)-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-benzamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-dimethoxy-benzamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-fluoro-benzamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(3-methoxy-phenyl)-acetamide;

2-(3,4-Dimethoxy-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-thiophen-2-yl-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(4-fluoro-phenyl)-acetamide;

N-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzamide;

1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

N-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-phenyl-acetamide; and

1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide.

28. (Currently amended) ~~Pharmaceutical compositions containing A~~
~~pharmaceutical composition comprising~~ a compound of any one of claims 1, [[to 27]] 25,
26 or 27, and ~~usual pharmaceutically acceptable~~ carrier materials and adjuvants ~~for the~~
~~treatment of disorders which are associated with a dysregulation of urotensin II or~~
~~urotensin II receptors, or disorders associated with vascular or myocardial dysfunction,~~

~~comprising hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, or pulmonary fibrosis.~~

29. (Cancelled).

30. (Cancelled).

31. (Cancelled).

32. (Currently amended) ~~[[The]]~~ A method of treating a patient suffering from a disorder ~~given in any one of claims 28 to 31 by~~ associated with a dysregulation of urotensin II or urotensin II receptors, or disorders associated with vascular or myocardial dysfunction, selected from the group consisting of hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine, subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, and pulmonary fibrosis, said method comprising administering ~~[[a]]~~ the pharmaceutical composition according to ~~any one of claims 28 and 29~~ claim 28.

33. (New) The method of claim 32, further comprising administering an additional pharmacologically active compound.

34. (New) The method of claim 33, wherein said additional pharmacologically active compound is selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, beta-adrenergic antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators.

35. (New) A method of treating a patient suffering from a disorder selected from the group consisting of restenosis after balloon or stent angioplasty, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, and neurodegenerative diseases, said method comprising administering the pharmaceutical composition of claim 28.

36. (New) The method of claim 35, further comprising administering an additional pharmacologically active compound.

37. (New) The method of claim 36, wherein said additional pharmacologically active compound is selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, beta-adrenergic antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.